Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 64.8792
- Book/Share 13.8067
- PB 20.4394
- Debt/Equity 7.5665
- CurrentRatio 1.3056
- ROIC 0.1044
- MktCap 151925714352.0
- FreeCF/Share 19.7119
- PFCF 14.3259
- PE 22.9375
- Debt/Assets 0.6394
- DivYield 0.0333
- ROE 0.9792
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMGN | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
| Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
| Initiation | AMGN | Cantor Fitzgerald | -- | Overweight | -- | $405 | Sept. 27, 2024 |
News
Amgen Shares Cross Above 200 DMA
Published: October 01, 2025 by: Forbes
Sentiment: Positive
In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Goldman Sachs Sees 4 Rate Cuts by Next Summer: 5 High-Yield Dividend Winners
Published: September 26, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks because they offer a significant income stream and have massive total return potential.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
Published: September 26, 2025 by: PRNewsWire
Sentiment: Neutral
THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.
Read More
Amgen: Imdelltra Could Be The Next Game Changer
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Positive
Despite the political noise coming out of the White House over efforts to lower drug prices, Amgen Inc.'s oncology franchise has continued to deliver strong performance since the start of 2025. So, AMGN's sales of Imdelltra, which is rapidly capturing the lung cancer therapeutics market, reached $134 million in Q2 2025, an impressive 1016.7% increase year-over-year. Also, thanks to the synergy effects from the acquisition of Horizon, as well as growing demand for Blincyto, AMGN's gross profit margin reached 70.9%, 9.5% higher than in Q2 2024.
Read More
Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen Inc. (NASDAQ:AMGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Peter Griffith - Executive VP & CFO Kave Niksefat - Senior Vice President of Global Marketing & Access Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.
Read More
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen Inc. (NASDAQ:AMGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capparelli Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst So we have Paul Burton. He's the Chief Medical Officer of the company; and dabbing for the first time, Adam Elinoff, the new IR at Amgen.
Read More
Investing in the Age of Longevity: Silver Economy Stocks in Focus
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Read More
Here's Why Amgen (AMGN) is a Strong Value Stock
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
Published: August 27, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
Read More
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
Published: August 25, 2025 by: PRNewsWire
Sentiment: Neutral
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
Published: August 14, 2025 by: Seeking Alpha
Sentiment: Positive
Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.
Read More
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Positive
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow dividend stocks could deliver 14.93% to 41.48% net gains by August 2026, with an average estimated gain of 23.33%. Most Dow stocks remain overpriced relative to their dividends, but market pullbacks or dividend increases could bring more into fair-value territory for income investors.
Read More
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Published: August 06, 2025 by: Benzinga
Sentiment: Negative
Amgen Inc. AMGN shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.
Read More
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.
Read More
Trade Deficit Narrowed More Than Expected
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pre-market futures are in the green across major indexes this morning, but experiencing a bit of choppiness. The Dow and S&P 500 are both up mere single-digits at this hour, off the early-morning highs, while the tech-heavy Nasdaq stays up +70 points presently.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Buy or Sell Amgen Stock Ahead of Its Earnings?
Published: August 04, 2025 by: Forbes
Sentiment: Negative
Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a tendency to experience negative one-day returns following its earnings announcements.
Read More
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Read More
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000